Sugi Predict

Sugi Predict / Compounds / SCHEMBL10241524

SCHEMBL10241524

SCHEMBL10241524

CC(C)(C)OC(=O)NCCCC[C@@H](NC(=O)OC(C)(C)C)C(=O)O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 2/20 0.65
▸ KMT2A Q03164 2/20 0.65
▸ GAA P10253 1/20 0.65
▸ TDP1 Q9NUW8 2/20 0.55
▸ CTSK P43235 6/20 0.52
▸ CTSS P25774 3/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ TSHR P16473 1/20 0.52
▸ ATM Q13315 1/20 0.49
▸ MAOA P21397 1/20 0.49
▸ MAOB P27338 1/20 0.49
▸ CAPN1 P07384 1/20 0.48
▸ POLB P06746 1/20 0.47
▸ NPSR1 Q6W5P4 1/20 0.47
▸ CA1 P00915 4/20 0.47
▸ CA2 P00918 4/20 0.47
▸ CA12 O43570 2/20 0.47
▸ CA9 Q16790 2/20 0.47
▸ FOLH1 Q04609 1/20 0.47
▸ TGM2 P21980 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391537 1.00 MEN1 (0.65) MEN1KMT2AGAATDP1CTSK
SCHEMBL3445777 1.00 MEN1 (0.65) MEN1KMT2AGAATDP1CTSK
SCHEMBL21702752 0.98 MEN1 (0.63) MEN1KMT2AGAATDP1CTSK
Hydrochloric Acid SCHEMBL28881882 0.98 MEN1 (0.63) MEN1KMT2AGAATDP1CTSK
Hydrochloric Acid SCHEMBL28881885 0.98 MEN1 (0.63) MEN1KMT2AGAATDP1CTSK
SCHEMBL4888105 0.95 MEN1 (0.71) MEN1KMT2AGAATDP1CTSK
SCHEMBL903957 0.95 MEN1 (0.71) MEN1KMT2AGAATDP1CTSK
SCHEMBL12238298 0.95 MEN1 (0.71) MEN1KMT2AGAATDP1CTSK
SCHEMBL13702218 0.94 MEN1 (0.58) MEN1KMT2AGAATDP1CTSK
SCHEMBL16504731 0.94 MEN1 (0.58) MEN1KMT2AGAATDP1CTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118924682-A Difunctional dendritic lipopeptide nano micelle and preparation method and application thereof 中国药科大学 2024-11-12 — — CN claimed
CN-116874803-A Antibacterial dendritic polyester polymer and preparation method and application thereof 清华大学深圳国际研究生院 2023-10-13 — — CN claimed
EP-3988538-A1 MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF Zhejiang Zhida Pharmaceutical Co., Ltd. (CN) 2022-04-27 — — EP claimed
US-20220111055-A1 MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) 2022-04-14 — — US claimed
WO-2020252713-A1 MODIFIED HYDROPHOBIC AUXILIARY MATERIAL, PREPARATION METHOD THEREFOR AND USE THEREOF 浙江智达药业有限公司 2020-12-24 — — WO claimed
CN-112110834-A Modified hydrophobic auxiliary material and preparation method and application thereof 浙江智达药业有限公司 2020-12-22 — — CN claimed
US-12616676-B2 Preparation method and use of modified hydrophobic excipient ZHEJIANG ZHIDA PHARMACEUTICAL CO., LTD. (CN) 2026-05-05 — — US disclosed
EP-4637826-A1 CONJUGATE COMPOUNDS AND THEIR USE IN CANCER TREATMENT AND DIAGNOSIS Technische Universität München (DE) 2025-10-29 — — EP disclosed
US-20250304645-A1 Prodrugs of GLP-1 Polypeptide and Uses Thereof NOVO NORDISK A/S (DK) 2025-10-02 — — US disclosed
WO-2025090774-A1 CHEMOTHERAPEUTIC COMPOUNDS AND METHODS OF USE SEAGEN INC. (US) 2025-05-01 — — WO disclosed
CN-119841819-A Degradation agent for targeting BCR-ABL and application thereof 北京大学 2025-04-18 — — CN disclosed
EP-4522220-A1 PRODRUGS OF GLP-1 POLYPEPTIDE AND USES THEREOF Novo Nordisk A/S (DK) 2025-03-19 — — EP disclosed
CN-119529019-A Small molecule active peptide and preparation method and application thereof 广州朗圣药业有限公司 2025-02-28 — — CN disclosed
US-20110201559-A1 New Optically Pure Compounds for Improved Therapeutic Efficiency CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) 2011-08-18 — — US disclosed
US-20110201559-A1 New Optically Pure Compounds for Improved Therapeutic Efficiency CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) 2011-08-18 — — US disclosed
WO-2009141687-A1 NEW OPTICALLY PURE COMPOUNDS FOR IMPROVED THERAPEUTIC EFFICIENCY CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2009-11-26 — — WO disclosed
US-20090163705-A1 CATIONIC LIPIDS ALNYLAM PHARMACEUTICALS, INC. (US) 2009-06-25 — — US disclosed
US-20090036353-A1 Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers NOVO NORDISK A/S (DK) 2009-02-05 — — US disclosed
US-20090036353-A1 Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers NOVO NORDISK A/S (DK) 2009-02-05 — — US disclosed
US-20080287396-A1 Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections TARGANTA THERAPEUTICA INC. (CA) 2008-11-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12616676-B2 Preparation method and use of modified hydrophobic excipient CETP, LIPA, MTTP MEN1 4516/4885KMT2A 855/4885GAA 905/4885
US-20080287396-A1 Phosphonated Fluoroquinolones, Antibacterial Analogs Thereof, and Methods for the Prevention and Treatment of Bone and Joint Infections BPGM, PSPH, PGLS MEN1 2424/4885KMT2A 4190/4885GAA 1879/4885
US-20110201559-A1 New Optically Pure Compounds for Improved Therapeutic Efficiency VIP, PEPD, PTMA MEN1 1205/4885KMT2A 4334/4885GAA 3970/4885
US-20220111055-A1 MODIFIED HYDROPHOBIC EXCIPIENT AND PREPARATION METHOD THEREOF CETP, SLC43A1, SLC27A1 MEN1 543/4885KMT2A 2845/4885GAA 3742/4885
US-20090163705-A1 CATIONIC LIPIDS CETP, SGMS1, SGMS2 MEN1 1780/4885KMT2A 4374/4885GAA 1973/4885
US-20090036353-A1 Insulin Derivatives Conjugated with Structurally Well Defined Branched Polymers INSR, IAPP, IGF1R MEN1 278/4885KMT2A 4457/4885GAA 879/4885
US-20250304645-A1 Prodrugs of GLP-1 Polypeptide and Uses Thereof GLP1R, IAPP, GCG MEN1 480/4885KMT2A 2711/4885GAA 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.